A Study to Evaluate the Intramuscular Administration of Scopolamine
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To characterize the safety and tolerability profile of ascending doses of scopolamine
hydrobromide trihydrate (Scopolamine HBT) administered by intramuscular (IM) injection. And
characterize the pharmacokinetics (PK) of ascending doses of Scopolamine HBT administered by
IM injection
Phase:
Phase 1
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command